Bar-Yehuda S - Search Results

1

A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model.

Merimsky O, Meller I, Inbar M, Bar-Yehuda S, Shoenfeld Y, Fishman P. Merimsky O, et al. Int J Oncol. 2002 Apr;20(4):839-43. Int J Oncol. 2002. PMID: 11894134

2

IVIg to prevent tumor metastases (Review).

Fishman P, Bar-Yehuda S, Shoenfeld Y. Fishman P, et al. Int J Oncol. 2002 Oct;21(4):875-80. Int J Oncol. 2002. PMID: 12239629 Review.

3

A3 adenosine receptor agonist potentiates natural killer cell activity.

Harish A, Hohana G, Fishman P, Arnon O, Bar-Yehuda S. Harish A, et al. Int J Oncol. 2003 Oct;23(4):1245-9. Int J Oncol. 2003. PMID: 12964011

4

Mononuclear cells release low molecular weight factors with anti-cancer activity: A lower level of production by cells of cancer patients.

Cohen-Aloro D, Merimsky O, Bar-Yehuda S, Klein B, Kayzer S, Fishman P. Cohen-Aloro D, et al. Int J Oncol. 1998 Apr;12(4):921-5. doi: 10.3892/ijo.12.4.921. Int J Oncol. 1998. PMID: 9499456

5

Pharmacology and therapeutic applications of A3 receptor subtype.

Fishman P, Bar-Yehuda S. Fishman P, et al. Curr Top Med Chem. 2003;3(4):463-9. doi: 10.2174/1568026033392147. Curr Top Med Chem. 2003. PMID: 12570762 Review.

6

Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth.

Fishman P, Bar-Yehuda S, Vagman L. Fishman P, et al. Cancer Res. 1998 Jul 15;58(14):3181-7. Cancer Res. 1998. PMID: 9679987

7

Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice.

Bar-Yehuda S, Farbstein T, Barer F, Ohana G, Fishman P. Bar-Yehuda S, et al. Clin Exp Metastasis. 1999;17(6):531-5. doi: 10.1023/a:1006649617918. Clin Exp Metastasis. 1999. PMID: 10763920

8

Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists.

Bar-Yehuda S, Barer F, Volfsson L, Fishman P. Bar-Yehuda S, et al. Neoplasia. 2001 Mar-Apr;3(2):125-31. doi: 10.1038/sj.neo.7900138. Neoplasia. 2001. PMID: 11420748 Free PMC article.

9

A3 adenosine receptor as a target for cancer therapy.

Fishman P, Bar-Yehuda S, Madi L, Cohn I. Fishman P, et al. Anticancer Drugs. 2002 Jun;13(5):437-43. doi: 10.1097/00001813-200206000-00001. Anticancer Drugs. 2002. PMID: 12045454 Review.

10

Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents.

Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, Cohn S, Fishman P. Bar-Yehuda S, et al. Exp Hematol. 2002 Dec;30(12):1390-8. doi: 10.1016/s0301-472x(02)00962-1. Exp Hematol. 2002. PMID: 12482500 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters